申请人:Merck & Co., Inc.
公开号:US05595996A1
公开(公告)日:1997-01-21
Compounds of the Formula I ##STR1## wherein: the dotted line indicates that a double bond may be present or absent; R.sup.1 is H, methyl or ethyl; R.sup.2 is .alpha.- or .beta.-C.sub.1-10 straight or branched alkyl; R.sup.3 is CO.sub.2 H, CN, CO.sub.2 R.sup.4, COHNR.sup.4, or CON(R.sup.4).sub.2 ; R.sup.4 is H, C.sub.1-10 straight or branched alkyl, aryl, heteroaryl, or aralkyl; Aryl is phenyl, substituted phenyl, naphthyl, or biphenyl; Heteroaryl is pyridyl, pyrrolyl, thienyl, furanyl or quinolinyl; and Aralkyl is C.sub.1-10 alkyl substituted with one to three phenyl or substituted phenyl moieties; and their pharmaceutically acceptable salts are described. These compounds are 5.alpha.-reductase type 1 inhibitors. They may be used for treating conditions associated with an excess of DHT, either alone or in combination with other 5.alpha.-reductase inhibitors.
化合物的式子为I ##STR1## 其中:点线表示双键可以存在或不存在;R.sup.1为H,甲基或乙基;R.sup.2为α-或β-C.sub.1-10直链或支链烷基;R.sup.3为CO.sub.2 H,CN,CO.sub.2 R.sup.4,COHNR.sup.4或CON(R.sup.4).sub.2;R.sup.4为H,C.sub.1-10直链或支链烷基,芳基,杂环芳基或芳基烷基;芳基为苯基,取代苯基,萘基或联苯基;杂环芳基为吡啶基,吡咯基,噻吩基,呋喃基或喹啉基;芳基烷基为C.sub.1-10烷基,取代有一到三个苯基或取代苯基基团;并描述了其药物可接受的盐。这些化合物是5α-还原酶类型1的抑制剂。它们可以用于治疗与DHT过量有关的疾病,单独使用或与其他5α-还原酶抑制剂联合使用。